A jury in New York on Friday awarded $8 million in damages in a product-liability case over Merck & Co.’s (MRK) osteoporosis drug Fosamax.
The verdict is the first loss for the Whitehouse Station, N.J., drug maker as it faces hundreds of lawsuits in state and federal court over allegations Fosamax can cause a jaw-destroying condition known as osteonecrosis. Get the full story »
